The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy
Abroad (travel likely)RecruitingPHASE2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Locations
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Texas Health Science Center at Houston, Houston, Texas, United States
- University of Washington, Seattle, Washington, United States